Publications by authors named "Philippe Wiesel"

Claim this Profile
S
Setanaxib, a first-in-class selective NADPH oxidase 1/4 inhibitor for primary biliary cholangitis: A randomized, placebo-controlled, phase 2 trial.
Pietro Invernizzi, Marco Carbone, David Jones, Cynthia Levy, Nicola Little, Philippe Wiesel

Liver Int· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial.
David Jones, Marco Carbone, Pietro Invernizzi, Nicola Little, Frederik Nevens, Philippe Wiesel

Hepatol Commun· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.
Kirsty Ford, Christopher J Hanley, Massimiliano Mellone, Cedric Szyndralewiez, Freddy Heitz, Philippe Wiesel

Cancer Res· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the NADPH Oxidase-4 and Liver X Receptor Pathway Preserves Schwann Cell Integrity in Diabetic Mice.
Stéphanie A Eid, Mohamed El Massry, Mehdi Hichor, Mary Haddad, Julien Grenier, Philippe Wiesel

Diabetes· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial.
Sylviane Muller, Fanny Monneaux, Nicolas Schall, Rasho K Rashkov, Boycho A Oparanov, Philippe Wiesel

Arthritis Rheum· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis